Savonix and Fujitsu Connected Technologies Limited Partner to Introduce Savonix Mobile App on Raku-Raku Smartphone F-42A
29.9.2020 14:15:00 EEST | Business Wire | Press release
Savonix, a global leader in digital cognitive health testing, and Fujitsu Connected Technologies Limited (FCNT), one of the major smartphone manufacturers in Japan, unveiled Savonix Mobile–a digital cognitive testing app–on the Raku-Raku Smartphone F-42A.
More than 4.6 million people in Japan are suffering from some form of dementia, with the total expected to soar to about 7.3 million people – or one in five Japanese aged 65 or over – by 2025. Japan’s government last year announced aims to reduce dementia cases by 6 percent in those aged 70 and older over the next six years.
Savonix Mobile, pre-installed on the Raku-Raku Smartphone F-42A, will allow users to test their cognition across eight brain functions such as executive function, working memory, and impulse control. Users will immediately receive test results within the app and will be able to take action to manage their cognitive health. Savonix Mobile detects mild cognitive impairment 93 percent of the time. For this reason, testing cognition is a good way to monitor your brain health over time. Recent studies presented at this year’s Alzheimer’s Association International Conference in July showed that up to 40 percent of dementias may be prevented by changing health habits such as diet, smoking, alcohol use, and sleep. Understanding your lifestyle risks can help you make smarter choices about brain health.
The Raku-Raku Smartphone will also house a pedometer and other important healthcare pre-installed applications to support and manage the user’s health.
“We’re excited about our partnership with FCNT as it will put easy and accurate cognitive testing into the hands of people who need it. This is impactful and aligns with how Japan and Japanese companies like FCNT are leading globally on the prevention of dementia,” said Savonix Founder and CEO Dr. Mylea Charvat. “Our digital cognitive assessment platform enables people to assess and monitor their brain health regularly and to incorporate lifestyle advice to improve brain wellness.”
“It is our great pleasure to have our Raku-Raku Smartphone F-42A equipped with the Savonix Mobile App,” said Katsumi Takada, President & Representative Director at FCNT. “This adoption enables services that support maintaining brain health and reducing the risk of dementia for users. We expect that this will make people more conscious about their health and help them lead a healthier life.”
About Savonix
A global leader in cognitive health, Savonix delivers the only neuropsychology platform in the market. Savonix provides digital cognitive health solutions and empowers healthcare providers, payers, and researchers to evaluate and leverage results to improve health and treatment outcomes. Developed by clinical neuropsychologists and digital health technology experts, the Savonix Cognitive Assessment is an accurate, accessible, and affordable tool available for download on all mobile devices. To learn more about Savonix, visit Savonix.com.
About Fujitsu Connected Technologies
Fujitsu Connected Technologies Limited was established in February 2016 through the spinoff of Fujitsu Limited’s mobile phone business. To create a future where people live their lives fully with peace of mind, FCNT connects people, things, and services in a more comfortable way with transcendental ideas and advanced technologies. FCNT has led the way in its integration of healthcare technologies into mobile phones since they introduced the world's first mobile phone with a pedometer in 2003. For more details, please visit https://www.fujitsu.com/jp/group/fcnt/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005016/en/
Contact information
Savonix
Reynald Hiole
+1 415.919.7421
rhiole@savonix.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom